ArticleDiscover oncology2026
Conservative management of perinatal adrenal masses in a single institution retrospective study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrenatal ultrasound screening has increased detection of adrenal masses during the fetal and neonatal periods, creating management dilemmas between immediate surgical intervention and observation. This study evaluates the outcomes of selective conservative management in perinatal adrenal masses.
methodsWe conducted a single-institution retrospective case series of nine patients with perinatal adrenal masses diagnosed at our institution between 2015 and 2025. Clinical presentation, imaging characteristics, biochemical markers, treatment decisions, and outcomes were analyzed. The cohort included five males and four females, with masses detected prenatally in five cases. All patients were initially managed conservatively with serial imaging surveillance to assess lesion volume over time.
resultsNeuroblastoma was confirmed in four patients; other diagnoses included four benign lesions and one adrenocortical carcinoma. Given the small sample size of this case series, the following proportions should be interpreted with caution and are not intended to reflect population-level outcomes. Spontaneous regression occurred in six cases, two remained stable, and one increased in size. Four patients underwent surgical intervention based on growth patterns or radiological suspicion of malignancy. Median follow-up was 42 months (range: 6 months to 10 years), with no mortality recorded.
conclusionAmong the nine case, we observed spontaneous regression in six of nine patients. Temporal evolution of lesion volume proved more informative for clinical decision-making than initial imaging characteristics. The adrenocortical carcinoma case illustrates that radiological trend alone does not always determine management, and that clinical context-including genetic predisposition-must guide decisions. Although our small cohort precludes generalizable conclusions, this institutional experience contributes to the growing evidence base supporting observational approaches in appropriately selected cases. Larger prospective studies incorporating molecular and genetic characterization remain essential to identify reliable predictors of lesion behavior and to optimize patient selection for conservative versus surgical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.